NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Innate Pharma S.A. (NASDAQ:IPHA) on behalf of Innate stockholders. Our investigation concerns whether Innate has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On September 8, 2020, Innate announced sudden changes to its $100 million deal with AstraZeneca. Innate would no longer receive a $100 million payment when it started its first Phase 3 clinical trial of monalizumab. Instead the company would receive $50 million at the start of the trial and another $50 million when interim analysis proved clinical activity.
Following this news, Innate American Depositary shares dropped $1.62 per share, or over 26.6%, to close at $4.45 per share.
If you purchased or otherwise acquired Innate Pharma shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at email@example.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.